News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eli Lilly and Company (LLY)'s Bydureon Diabetes Drug Recommended by UK Cost Agency



10/18/2011 7:45:54 AM

Eli Lilly & Co. (LLY)’s Bydureon diabetes drug was approved by the U.K.’s health-cost agency for use in combination with two glucose-lowering medicines. Bydureon can be used with metformin and a sulphonylurea, or metformin and a thiazolidinedione, when control of blood sugar is inadequate, the National Institute for Health and Clinical Excellence said in a statement today. Lilly, whose top-selling schizophrenia drug Zyprexa loses U.S. patent protection this month, is seeking clearance to sell Bydureon in the U.S.

Read at Bloomberg
Read at InPharm.com
Read at Daily Mail UK
Read at Nasdaq
Read at Pharma Times [Free Reg Req'd]


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES